Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

HARP

Harpoon Therapeutics Inc

Dec 06 • 04:00PM ET

10.03

Dollar change -0.59
Percentage change -5.56	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-8.71	Insider Own	30.33%	Shs Outstand	16.93M	Perf Week	-2.81%
Market Cap	169.81M	Forward P/E	-	EPS next Y	-3.12	Insider Trans	0.00%	Shs Float	11.80M	Perf Month	68.29%
Income	-30.50M	PEG	-	EPS next Q	-0.61	Inst Own	25.98%	Short Float / Ratio	2.16% / 1.46	Perf Quarter	25.53%
Sales	37.34M	P/S	4.55	EPS this Y	88.38%	Inst Trans	-8.84%	Short Interest	0.26M	Perf Half Y	29.07%
Book/sh	1.11	P/B	9.08	EPS next Y	-31.52%	ROA	-46.54%	Target Price	14.10	Perf Year	39.19%
Cash/sh	1.87	P/C	5.37	EPS next 5Y	-	ROE	-284.33%	52W Range	3.11 - 33.55	Perf YTD	38.21%
Dividend	-	P/FCF	-	EPS past 5Y	-24.57%	ROI	-189.78%	52W High	-70.10%	Beta	2.09
Dividend %	-	Quick Ratio	1.89	Sales past 5Y	173.00%	Gross Margin	92.45%	52W Low	222.51%	ATR	1.35
Employees	50	Current Ratio	1.89	Sales Q/Q	-67.33%	Oper. Margin	-100.14%	RSI (14)	55.32	Volatility	13.38% 15.60%
Optionable	No	Debt/Eq	3.19	EPS Q/Q	87.04%	Profit Margin	-81.68%	Rel Volume	1.27	Prev Close	10.62
Shortable	Yes	LT Debt/Eq	2.54	Earnings	Nov 09 AMC	Payout	-	Avg Volume	175.38K	Price	10.03
Recom	1.57	SMA20	2.89%	SMA50	50.42%	SMA200	40.92%	Volume	221,026	Change	-5.56%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Initiated	TD Cowen	Outperform
Jul-06-22	Resumed	Canaccord Genuity	Buy	$16
Sep-28-21	Upgrade	Citigroup	Neutral → Buy	$16
Jun-08-21	Downgrade	Citigroup	Buy → Neutral	$25 → $16
Jun-07-21	Downgrade	Wedbush	Outperform → Neutral
May-28-21	Initiated	Cantor Fitzgerald	Overweight	$40
May-10-21	Initiated	Piper Sandler	Overweight	$35
Dec-23-20	Resumed	H.C. Wainwright	Buy	$31
May-22-20	Initiated	Piper Sandler	Overweight	$35
Feb-28-20	Initiated	SunTrust	Buy
Feb-03-20	Initiated	H.C. Wainwright	Buy	$28
Nov-14-19	Initiated	ROTH Capital	Buy	$25
May-24-19	Resumed	Citigroup	Buy	$23
Apr-23-19	Initiated	Robert W. Baird	Outperform
Mar-05-19	Initiated	Wedbush	Outperform	$23

Show Previous Ratings

Dec-05-23 12:00PM	Harpoon Therapeutics, Inc. (HARP) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Nov-30-23 11:07AM	Is it a Good Idea to Invest in Harpoon (HARP) Stock Now? (Zacks)
09:55AM	Wall Street Analysts Believe Harpoon Therapeutics, Inc. (HARP) Could Rally 40.5%: Here's is How to Trade (Zacks)
Nov-15-23 08:50AM	Fast-paced Momentum Stock Harpoon Therapeutics, Inc. (HARP) Is Still Trading at a Bargain (Zacks)
Nov-14-23 09:55AM	Wall Street Analysts See a 92.31% Upside in Harpoon Therapeutics, Inc. (HARP): Can the Stock Really Move This High? (Zacks) +15.25%
04:01PM	Loading…
Nov-09-23 04:01PM	Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-23 09:15AM	Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition (GlobeNewswire)
Oct-23-23 07:17AM	Harpoon Therapeutics Announces Up to $150 Million Private Placement (GlobeNewswire) -23.26%
Oct-21-23 11:31AM	Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023 (GlobeNewswire)
Oct-16-23 04:05PM	Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023 (GlobeNewswire)
Oct-09-23 04:17PM	Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023 (GlobeNewswire) -11.53%
Sep-28-23 03:00AM	Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting (GlobeNewswire)
Sep-15-23 07:15AM	Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort (GlobeNewswire) -6.48%
Sep-13-23 04:05PM	Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie (GlobeNewswire)
Sep-06-23 07:30AM	Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting (GlobeNewswire)
08:05AM	Loading…
Sep-05-23 08:05AM	Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023 (GlobeNewswire)
08:00AM	Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September (GlobeNewswire)
Aug-09-23 05:40PM	Harpoon Therapeutics, Inc. (HARP) Beats Q2 Earnings and Revenue Estimates (Zacks)
04:01PM	Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-03-23 07:30AM	Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August (GlobeNewswire)
Aug-01-23 07:30AM	Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development (GlobeNewswire)
Jul-10-23 09:00AM	Replicate Bioscience Appoints Rachael Lester as Chief Business Officer (PR Newswire) +5.13%
Jun-27-23 07:30AM	Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma (GlobeNewswire) +5.80%
Jun-26-23 05:14PM	3 Penny Stocks with Multibagger Potential for the Second Half of 2023 (InvestorPlace)
May-28-23 08:24AM	Analysts Just Shipped A Meaningful Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Estimates (Simply Wall St.)
May-11-23 05:55PM	Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:30PM	Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-23 05:25PM	Chinook Therapeutics (KDNY) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +7.10%
Apr-18-23 01:30PM	Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023 (GlobeNewswire) -6.10%
Apr-17-23 01:30PM	Harpoon Therapeutics Presents Data for New ProTriTAC Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023 (GlobeNewswire)
04:05PM	Loading…
Apr-10-23 04:05PM	Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference (GlobeNewswire)
Apr-01-23 08:40AM	News Flash: 8 Analysts Think Harpoon Therapeutics, Inc. (NASDAQ:HARP) Earnings Are Under Threat (Simply Wall St.)
Mar-29-23 06:24AM	Harpoon Therapeutics Full Year 2022 Earnings: Misses Expectations (Simply Wall St.)
Mar-27-23 04:05PM	Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
04:02PM	Harpoon Therapeutics Announces Closing of $25 Million Private Placement (GlobeNewswire)
Mar-14-23 06:21PM	Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023 (GlobeNewswire)
Feb-08-23 07:50AM	We're A Little Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate (Simply Wall St.) -21.17%
Feb-07-23 07:30AM	Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire) +21.24%
Feb-02-23 11:28AM	The 3 Most Undervalued Penny Stocks to Buy in February 2023 (InvestorPlace) -7.27%
Jan-25-23 08:50AM	Why Fast-paced Mover Harpoon Therapeutics, Inc. (HARP) Is a Great Choice for Value Investors (Zacks)
Dec-16-22 12:09PM	7 Stocks to Add to Your 10x Watchlist (InvestorPlace) -5.45%
Dec-12-22 07:37AM	Harpoon Therapeutics Shares Gain On Updated Data From Investigational Myeloma Drug (Benzinga) +22.61%
Dec-11-22 10:00AM	Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Dec-05-22 07:30AM	Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022 (GlobeNewswire)
Nov-21-22 04:59PM	Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-19-22 07:12AM	Analysts Just Published A Bright New Outlook For Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) (Simply Wall St.)
Nov-14-22 05:25PM	Harpoon Therapeutics, Inc. (HARP) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-03-22 09:09AM	Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition (GlobeNewswire)
Oct-04-22 07:30AM	Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer (GlobeNewswire) +7.41%
Sep-19-22 04:05PM	Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors (GlobeNewswire) -10.07%
Sep-01-22 07:30AM	Harpoon Therapeutics to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-17-22 06:07AM	Analysts Just Made A Major Revision To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Revenue Forecasts (Simply Wall St.)
Aug-10-22 05:15PM	Harpoon Therapeutics, Inc. (HARP) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
07:32AM	Shareholders in Harpoon Therapeutics (NASDAQ:HARP) are in the red if they invested three years ago (Simply Wall St.)
Aug-02-22 07:30AM	Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Jul-26-22 07:19AM	Strength Seen in ProPhase Labs, Inc. (PRPH): Can Its 8% Jump Turn into More Strength? (Zacks)
Jul-06-22 07:30AM	Harpoon Therapeutics Expands Leadership Team (GlobeNewswire)
Jun-27-22 12:50PM	Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation (Simply Wall St.)
04:15AM	Aziyo Biologics, Inc. (AZYO) Moves 7.8% Higher: Will This Strength Last? (Zacks)
May-26-22 05:00PM	Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting (GlobeNewswire)
May-14-22 08:20AM	Growth Investors: Industry Analysts Just Upgraded Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Revenue Forecasts By -16% (Simply Wall St.)
May-12-22 05:25PM	Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-04-22 04:06PM	Cancer Drug Developers Trade Below Liquid Assets With No Respite In Sight (Bloomberg)
May-02-22 09:00AM	Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer (GlobeNewswire)
Apr-18-22 10:56AM	Insiders who bought this year lost US$50k as Harpoon Therapeutics, Inc. (NASDAQ:HARP) sheds US$30m in value (Simply Wall St.) -7.08%
Apr-12-22 07:30AM	Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome (GlobeNewswire) -11.38%
Apr-07-22 04:05PM	Harpoon Therapeutics Announces Leadership Change (GlobeNewswire)
07:30AM	Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference (GlobeNewswire)
Mar-11-22 10:53AM	Harpoon Therapeutics Discontinues Its Once Lead Prostate Cancer Candidate (Benzinga) -27.36%
Mar-10-22 05:45PM	Harpoon Therapeutics, Inc. (HARP) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:04PM	Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-08-22 06:55PM	Invacare (IVC) Q4 Earnings Top Estimates (Zacks) +6.61%
Mar-07-22 07:30AM	Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer (GlobeNewswire) +12.38%
Mar-03-22 04:23AM	Shareholders in Harpoon Therapeutics (NASDAQ:HARP) are in the red if they invested a year ago (Simply Wall St.)
Mar-02-22 07:30AM	Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217 (GlobeNewswire) +16.25%
Mar-01-22 10:15AM	Billionaire Steven Cohen Loads Up on These 2 Penny Stocks (TipRanks)
Feb-28-22 05:45PM	FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -6.18%
Feb-09-22 07:30AM	Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference (GlobeNewswire) +6.60%
Jan-12-22 10:00AM	Wall Street Analysts See a 274% Upside in Harpoon Therapeutics, Inc. (HARP): Can the Stock Really Move This High? (Zacks) -8.58%
Jan-11-22 08:00AM	Harpoon Therapeutics Provides Pipeline Development Milestones for 2022 (GlobeNewswire)
Dec-13-21 04:05PM	Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms (GlobeNewswire) +6.70%
Dec-11-21 09:00AM	Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition (GlobeNewswire)
Dec-07-21 07:30AM	Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021 (GlobeNewswire) +6.91%
Nov-12-21 07:00AM	Harpoon Therapeutics Presents Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire)
Nov-10-21 06:05PM	Harpoon Therapeutics, Inc. (HARP) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-09-21 04:01PM	Harpoon Therapeutics to Participate in Two Upcoming Virtual Investor Conferences (GlobeNewswire)
Nov-04-21 09:00AM	Harpoon Therapeutics to Present at the 63rd ASH Annual Meeting and Exposition (GlobeNewswire)
Oct-27-21 03:03PM	Harpoon Therapeutics, Inc. (HARP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-26-21 04:15PM	Harpoon Therapeutics Announces Change to Management Team and Board of Directors (GlobeNewswire)
Oct-05-21 07:30AM	Harpoon Therapeutics to Present Preclinical Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire)
Sep-25-21 09:24AM	Insider Buying: The Harpoon Therapeutics, Inc. (NASDAQ:HARP) Chief Financial Officer Just Bought 12% More Shares (Simply Wall St.)
Sep-02-21 07:30AM	Harpoon Therapeutics to Participate in Three Upcoming Virtual Investor Conferences (GlobeNewswire)
Aug-13-21 03:04AM	A Harpoon Therapeutics, Inc. (NASDAQ:HARP) insider increased their holdings by 13% last year (Simply Wall St.)
Aug-08-21 07:22PM	3 Strong Buy Stocks That Just Bottomed (TipRanks)
Aug-05-21 06:55PM	Harpoon Therapeutics, Inc. (HARP) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Harpoon Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HUNT RONALD	Director	Mar 23	Buy	1.00	10,000	10,000	10,000	Mar 27 05:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HARP

Harpoon Therapeutics Inc

Upgrade your FINVIZ experience